Tempus AI shares pulled back Friday after a five-day rally of nearly 40% driven by CEO Eric Lefkofsky's reimbursement projections at the ...

Tempus AI (TEM) stock jumped 15% Thursday after CEO projected up to $400M in Medicare revenue. The stock has rallied 92% since its July low of $41.55.

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

GSK (LSE: GSK) has delivered a 58.4% share price return over the past five years, putting real pressure on the question of whether current earnings justify ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

Tempus AI shares have surged nearly 30% this week after Morgan Stanley flagged a potential $330-400 million revenue boost.

Tempus AI (NASDAQ:TEM | TEM Price Prediction) is having a breakout week after Morgan Stanley remarks on September 15 ...

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

GSK will acquire a Chimagen trispecific T cell engager for multiple myeloma in a deal worth up to $750M. Here's what it means ...

GSK will acquire a trispecific T cell engager for multiple myeloma from Chimagen Biosciences in a deal worth up to $750 ...

GSK stock in London traded around 1,858.5 pence on September 15, 2026 after the company agreed a deal worth up to USD 750 million for a blood cancer drug. Berenberg raised its rating to Buy and lifted ...